[Form 4] BioCardia, Inc. Insider Trading Activity

Rhea-AI Filing Summary

BioCardia insider purchase reported on Form 4: Director Andrew Scott (reporting as Andy Blank Revocable Living Trust) purchased 288,000 shares of common stock and received 288,000 warrants on 09/19/2025 at a price of $1.25 per share/warrant bundle. After the transaction the reporting person beneficially owned 634,023 shares (direct/indirect holdings) and held warrants exercisable into 288,000 shares expiring 09/20/2027. The filing notes the shares are held in a revocable trust for which the reporting person is trustee. The Form 4 was signed by power of attorney on 09/23/2025.

Positive

• Insider purchase of 288,000 shares at $1.25 signals director conviction
• Matched warrants (288,000) exercisable into common stock provide potential upside
• Post-transaction beneficial ownership of 634,023 shares increases insider alignment with shareholders

Negative

• None.

Insights

Securities Analyst

TL;DR: Director bought a significant block at $1.25 and received matching warrants, signaling insider conviction without disclosure of financing source.

The 288,000-share purchase plus 288,000 warrants is a material insider acquisition relative to the post-transaction beneficial ownership of 634,023 shares. Acquiring shares alongside warrants at the same strike and term provides leveraged upside while the trust ownership suggests estate/holding vehicle rather than third-party purchase. Transaction price of $1.25 sets a recent private-market reference point for value. No information is provided on whether this was part of a larger financing or related-party arrangement; disclosure is limited to the holdings and dates.

Corporate Governance Expert

TL;DR: The filing documents an insider purchase through a revocable trust; governance implications are routine but worth monitoring for pattern.

The reporting person is a director and trustee of the Andy Blank Revocable Living Trust, which holds the shares indirectly. The paired issuance of common stock and warrants is documented and the warrants expire on 09/20/2027. This Form 4 is a standard Section 16 disclosure; it does not indicate any departure from governance norms or related-party conflicts based solely on the information provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blank Andrew Scott

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CA 94085

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/19/2025		P		288,000(1)	A	$1.25	634,023	I	See Footnote(2)
Common Stock								2,035	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant (right to buy)	$1.25	09/19/2025		P		288,000(1)		09/19/2025	09/20/2027	Common Stock	288,000(1)	(1)	602,522	I	See Footnote(2)

Explanation of Responses:

1. Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased.

2. These shares are held by Andy Blank Revocable Living Trust, of which the Reporting Person serves as trustee.

	/s/ David McClung, by power of attorney	09/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BioCardia director Andrew Scott (BCDA) report buying on Form 4?

The filing reports purchase of 288,000 shares of common stock and receipt of 288,000 warrants on 09/19/2025 at $1.25 per share/warrant bundle.

How many BioCardia shares does the reporting person beneficially own after the transaction?

After the reported transaction the reporting person beneficially owned 634,023 shares.

What are the terms and expiration of the warrants received in the transaction?

The warrants have an exercise price of $1.25, were issued on 09/19/2025, and expire on 09/20/2027.

Who holds the shares reported on the Form 4?

The shares are held by the Andy Blank Revocable Living Trust, for which the reporting person serves as trustee.

When was the Form 4 signed and filed?

The signature by power of attorney is dated 09/23/2025; the reported transaction date is 09/19/2025.